EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mesenchymal Stem Cells in the Treatment of COVID-19

Bei-Cyuan Guo iD, Kang-Hsi Wu iD, Chun-Yu Chen, Wen-Ya Lin, Yu-Jun Chang iD, Tai-An Lee, Mao-Jen Lin iD, Han-Ping Wu

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241914800 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Bei-Cyuan Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan. Hauptthemen laut MEDLINE: COVID-19, Mesenchymal Stem Cell Transplantation, Respiratory Distress Syndrome, Mesenchymal Stem Cells. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the emergence of the coronavirus disease 2019 (COVID-19) pandemic, many lives have been tragically lost to severe infections. The COVID-19 impact extends beyond the respiratory system, affecting various organs and functions. In severe cases, it can progress to acute respiratory distress syndrome (ARDS) and multi-organ failure, often fueled by an excessive immune response known as a cytokine storm. Mesenchymal stem cells (MSCs) have considerable potential because they can mitigate inflammation, modulate immune responses, and promote tissue regeneration. Accumulating evidence underscores the efficacy and safety of MSCs in treating severe COVID-19 and ARDS. Nonetheless, critical aspects, such as optimal routes of MSC administration, appropriate dosage, treatment intervals, management of extrapulmonary complications, and potential pediatric applications, warrant further exploration. These research avenues hold promise for enriching our understanding and refining the application of MSCs in confronting the multifaceted challenges posed by COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Mesenchymal Stem Cell TransplantationRespiratory Distress SyndromeMesenchymal Stem CellsHumansChildSARS-CoV-2

Stichwörter der Autor:innen

COVID-19mesenchymal stem celltreatment

Autor:innen und Institutionen

  • Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70403, Taiwan.
  • Department of Pediatrics, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
  • School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
  • Department of Emergency Medicine, Tungs' Taichung Metro Harbor Hospital, Taichung 43503, Taiwan.
  • Department of Nursing, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 35664, Taiwan.
  • Department of Pediatrics, Taichung Veterans General Hospital, Taichung 43503, Taiwan.

ORCID-Profile: Bei-Cyuan Guo, Kang-Hsi Wu, Yu-Jun Chang, Mao-Jen Lin

Zitieren

APA

Guo, B. C., Wu, K. H., Chen, C. Y., Lin, W. Y., Chang, Y. J., Lee, T. A., Lin, M. J., & Wu, H. P. (2023). Mesenchymal Stem Cells in the Treatment of COVID-19. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241914800

Vancouver

Guo BC, Wu KH, Chen CY, Lin WY, Chang YJ, Lee TA, et al. Mesenchymal Stem Cells in the Treatment of COVID-19. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241914800

BibTeX
@article{Guo2023,
  author = {Guo, Bei-Cyuan and Wu, Kang-Hsi and Chen, Chun-Yu and Lin, Wen-Ya and Chang, Yu-Jun and Lee, Tai-An and Lin, Mao-Jen and Wu, Han-Ping},
  title = {Mesenchymal Stem Cells in the Treatment of COVID-19},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241914800}
}
Kostenlos starten →